Learn more →
Back to Expert Scholars
dermatologic-oncology / dermatologic-oncologyMerkel Cell Carcinoma

Paul Nghiem

保罗·义

MD, PhD

🏢University of Washington / Fred Hutchinson Cancer Center(华盛顿大学/弗雷德·哈钦森癌症中心)🌐USA

Professor and Head, Division of Dermatology; Endowed Chair in Skin Oncology Research皮肤科主任教授;皮肤肿瘤学研究讲席教授

72
h-index
3
Key Papers
4
Awards
3
Key Contributions

👥Biography 个人简介

Paul Nghiem is the world's foremost expert on Merkel cell carcinoma (MCC), a rare and aggressive skin cancer. He led the pivotal trial of avelumab establishing the first FDA-approved therapy for MCC, identified the Merkel cell polyomavirus, and directs a comprehensive MCC clinical and research program at University of Washington.

Share:

🧪Research Fields 研究领域

Dermatologic Oncology皮肤肿瘤学
Merkel Cell Carcinoma梅克尔细胞癌
Skin Cancer Immunotherapy皮肤癌免疫治疗
Virus-Associated Cancers病毒相关癌症

🎓Key Contributions 主要贡献

Merkel Cell Carcinoma Immunotherapy

Led the pivotal JAVELIN Merkel 200 trial of avelumab, resulting in the first FDA approval of any therapy for metastatic Merkel cell carcinoma and transforming survival outcomes.

Merkel Cell Polyomavirus Research

Collaborated in characterizing the role of Merkel cell polyomavirus in MCC pathogenesis, providing biological rationale for the immunogenicity and immunotherapy sensitivity of MCC.

MCC Disease Registry and Natural History

Established a global MCC patient registry and natural history database, enabling population-level insights, prognostic markers, and streamlined clinical trial accrual.

Representative Works 代表性著作

[1]

PD-L1 Blockade with Avelumab for Metastatic Merkel Cell Carcinoma (JAVELIN Merkel 200)

Lancet Oncology (2016)

Pivotal study demonstrating durable responses with avelumab in chemotherapy-refractory MCC, leading to the first FDA approval for this aggressive skin cancer.

[2]

Programmed Death-1 Blockade with Pembrolizumab in Merkel Cell Carcinoma

Journal of Clinical Oncology (2016)

Established anti-PD-1 therapy as highly effective first-line treatment for MCC, with high response rates and prolonged durable remissions.

[3]

Merkel Cell Polyomavirus Is Commonly Present in and Transcriptionally Active in Merkel Cell Carcinomas

Journal of Investigative Dermatology (2009)

Confirmed widespread presence and transcriptional activity of MCPyV in MCC tumors, establishing the virus as central to MCC biology.

🏆Awards & Recognition 奖项与荣誉

🏆Society for Investigative Dermatology Distinguished Investigator Award
🏆Skin Cancer Foundation Research Award
🏆University of Washington Health Sciences Research Award
🏆NIH Rare Cancer Research Recognition

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 保罗·义 的研究动态

Follow Paul Nghiem's research updates

留下邮箱,当我们发布与 Paul Nghiem(University of Washington / Fred Hutchinson Cancer Center)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment